Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy

Int J Mol Sci. 2009 Mar;10(3):1000-12. doi: 10.3390/ijms10031000. Epub 2009 Mar 10.

Abstract

Spinal and bulbar muscular atrophy (SBMA) is a hereditary motor neuron disease caused by the expansion of a polyglutamine tract in the androgen receptor (AR). The histopathological finding in SBMA is loss of lower motor neurons in the anterior horn of the spinal cord as well as in the brainstem motor nuclei. Animal studies have revealed that the pathogenesis of SBMA depends on the level of serum testosterone, and that androgen deprivation mitigates neurodegeneration through inhibition of nuclear accumulation of the pathogenic AR. Heat shock proteins, ubiquitin-proteasome system and transcriptional regulation are also potential targets of therapy development for SBMA.

Keywords: Spinal and bulbar muscular atrophy (SBMA); androgen receptor (AR); leuprorelin acetate; polyglutamine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Heat-Shock Proteins / metabolism
  • Humans
  • Leuprolide / therapeutic use
  • Muscular Atrophy, Spinal / drug therapy
  • Muscular Atrophy, Spinal / metabolism
  • Muscular Atrophy, Spinal / pathology*
  • Peptides / genetics
  • Peptides / metabolism
  • Receptors, Androgen / metabolism
  • Testosterone / blood
  • Trinucleotide Repeats

Substances

  • Antineoplastic Agents, Hormonal
  • Heat-Shock Proteins
  • Peptides
  • Receptors, Androgen
  • polyglutamine
  • Testosterone
  • Leuprolide